A carregar...
LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody–Induced Tumor Cell Killing by Effector CD8(+) T Cells
Elicitation of tumor cell killing by CD8(+) T cells is an effective therapeutic approach for cancer. In addition to using immune checkpoint blockade to reinvigorate existing but unresponsive tumor-specific T cells, alternative therapeutic approaches have been developed, including stimulation of poly...
Na minha lista:
| Publicado no: | J Immunol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AAI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6680066/ https://ncbi.nlm.nih.gov/pubmed/31253728 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1801472 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|